Current stock page

Financial Data

SMMT Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

SMMTSummit Therapeutics Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$14.15−$0.92 (−6.14%)

Latest quote

  • Momentum
    65
  • Value
    —
  • Quality
    30
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0$0$0
Operating Income-$214.61M-$220.5M-$195.21M-$224.88M-$234.21M-$568.44M-$66.85M-$52.41M
Net Income-$208.39M-$215.7M-$189.42M-$219.17M-$231.79M-$565.71M-$62.91M-$48.89M
EPS-$0.26-$0.28-$0.24-$0.29-$0.31-$0.77-$0.09-$0.07
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$159.81M-$167.78M-$122.29M-$75.65M-$69.19M-$48.97M-$61.17M-$38.89M
Capital Expenditure-$396K-$968.2K-$245K-$121.71K-$52.78K$0-$422K-$11.19K
Free Cash Flow-$160.21M-$168.75M-$122.54M-$75.78M-$69.24M-$48.97M-$61.59M-$38.91M
Net Cash Provided By Operating Activities-$159.81M-$167.78M-$122.29M-$75.65M-$69.19M-$48.97M-$61.17M-$38.89M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$692.85M$752.19M$647.86M$751.18M$261.73M$324.04M$383.82M$435.56M
Total Debt$19.98M$20.38M$20.04M$20.89M$5.43M$5.55M$6.45M$7.22M
Cash And Cash Equivalents$150.81M$419.37M$106.52M$225.27M$238.55M$297.87M$211.53M$104.86M
Total Liabilities$128.17M$122.2M$101.92M$92.32M$69.47M$64.6M$39.49M$46.81M
Total Stockholders Equity$564.68M$629.98M$545.93M$658.86M$192.26M$259.44M$344.33M$388.75M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio20.0622.75—25.22—110.268.2744.73
P/S ratio————————
Debt To Equity0.040.030.040.030.030.020.020.02
Free Cash Flow Yield-4.39%-2.84%—-1.01%—-0.76%-0.75%-0.81%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio20.0622.75—25.22—110.268.2744.73
P/S ratio————————
Return On Equity-147.46%-135.89%-220.92%-163.86%-4.73%-282.83%-66.34%-53.76%
Debt To Equity0.040.030.040.030.030.020.020.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-13.22x
Pb20x
EPS Growth Yoy16.13%
Gross Margin0.00%
Operating Margin0.00%
ROE-138.81%
ROIC-145.82%
Debt To Equity0.04
FCF Yield-4.67%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$14.15
Volume5.56M
RSI (14)42.17
MACD-0.09
MACD signal-0.02
MACD histogram-0.06
ADX (14)13.95
SMA (50)$16.41
SMA (200)$16.15
ATR (14)$1.24
Historical volatility (annualized)108.69%
Volume (20-day average)4.84M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score38/100
Beta1.89
Annual volatility75.92%
Max Drawdown-52.88%
Sharpe Ratio-0.01
VaR (95%, 1-day)-7.14%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

SMMT Financial Data FAQ

What is Summit Therapeutics Inc.'s revenue?

Summit Therapeutics Inc.'s revenue is one of the core financial data points for SMMT. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Summit Therapeutics Inc.'s revenue growing?

Revenue growth shows whether Summit Therapeutics Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is SMMT's EPS?

SMMT's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Summit Therapeutics Inc.'s net income?

Summit Therapeutics Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Summit Therapeutics Inc. generate?

Free cash flow shows how much cash Summit Therapeutics Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Summit Therapeutics Inc. have?

Cash and debt help frame SMMT's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.